DHR - Danaher Corp Stock Analysis
Danaher Corp (DHR) is a publicly traded company listed on the NYSE. It operates in the Diagnostics & Research industry, part of the broader Healthcare sector. The company has a market capitalization of 143.62B, generates annual revenue of 23.82B, and reports net income of 3.77B. As of the latest data, the stock is trading at 200.68 USD.
From a valuation and risk perspective, the stock presents the following profile: The stock is moderately valued and aligns with market expectations for established companies. The PEG ratio is above 2, which could imply the stock is overvalued based on its growth outlook. The company maintains a healthy balance between debt and equity, which is typical for stable businesses. The dividend yield (0.6%) is modest, often associated with growth-oriented companies. This stock tends to be less volatile than the overall market, often preferred by conservative investors.
Analyst recommendation stands at Buy (4.26), indicating current market sentiment. Institutional ownership is reported at 81.51%, reflecting confidence from large investors. Over the last 12 months, the stock has shown a performance of -16.38%, trading within a 52-week range of 171.00 - 281.70.
DHR - Danaher Corp
200.68
Analyst Consensus
Buy 4.26
DHR – Analyst Rating Summary
- Strong Buy: 12
- Buy: 15
- Hold: 4
- Sell: 0
- Strong Sell: 0
- Total Analysts: 31
| Index: | S&P 500 | P/E: | 38.91 | EPS (ttm): | 5.16 | Insider Own: | 8.87% | Shs Outstand: | 715.60M | Perf Week: | 1.59% |
| Market Cap: | 143.62B | Forward P/E: | 23.42 | EPS next Y: | 8.57 | Insider Trans: | -1.96% | Shs Float: | 652.19M | Perf Month: | 4.44% |
| Income(ttm): | 3.77B | PEG: | 4.72 | EPS next Q: | 1.64 | Inst Own: | 81.51% | Short Float: | 1.19% | Perf Quarter: | 10.40% |
| Revenue(ttm): | 23.82B | P/S: | 6.03 | EPS this Y: | 3.05% | Inst Trans: | 0.48% | Short Ratio: | 1.92 | Perf Half Y: | -12.68% |
| Book/sh: | 71.06 | P/B: | 2.82 | EPS next Y: | 11.19% | ROA: | 4.63% | Short Interest: | 7.75M | Perf Year: | -16.38% |
| Cash/sh: | 2.78 | P/C: | 72.06 | EPS next 5Y: | 8.24% | ROE: | 7.22% | 52W Range: | 171.00 - 281.70 | Perf YTD: | -12.58% |
| Dividend Est.: | 1.21 (0.60%) | P/FCF: | 29.30 | EPS past 3/5Y: | -15.01% 9.03% | ROIC: | 5.63% | 52W High: | 281.70 -28.76% | Beta: | 0.74 |
| Dividend TTM: | 1.18 (0.59%) | Quick Ratio: | 1.05 | Sales past 3/5Y: | -6.76% 5.92% | Gross Margin: | 59.80% | 52W Low: | 171.00 17.36% | Perf 5Y: | 28.03% |
| Dividend Ex-Date: | Jun 27, 2025 | Current Ratio: | 1.43 | EPS Y/Y TTM: | -12.75% | Oper. Margin: | 21.67% | RSI (14): | 54.05 | Volatility: | 2.44% 2.26% |
| Employees: | 63000 | Debt/Eq: | 0.35 | Sales Y/Y TTM: | -9.19% | Profit Margin: | 15.81% | Recom: | 1.31 | Target Price: | 244.45 |
| Option/Short: | Yes / Yes | LT Debt/Eq: | 0.31 | EPS Q/Q: | -8.94% | Payout: | 20.42% | Rel Volume: | 1.05 | Prev Close: | 199.63 |
| Sales Surprise: | 3.04% | EPS Surprise: | 15.52% | Sales Q/Q: | -0.95% | Earnings: | Jul 22 BMO | Avg Volume: | 4.03M | Price: | 200.68 |
| SMA20: | 0.35% | SMA50: | 2.41% | SMA200: | -9.45% | Undervalued: 21.81% | Volume: | 4,225,543 | Change: | 0.53% | |
Graham Classic formula value: 115.74
(P/E=8 * 1g) Min value: 75.25
(current P/E * 2g) Max value: 256.65
Average value: 149.21
About Danaher Corp
Danaher Corp. engages in the design, manufacture, and marketing of professional, medical, industrial, and commercial products and services. It operates through the following segments: Biotechnology, Life Sciences, and Diagnostics. The Biotechnology segment includes bioprocessing, discovery, and medical businesses and offers a range of tools, consumables, and services. The Life Sciences segment offers a range of instruments and consumables to study the basic building blocks of life, including DNA and RNA. The Diagnostics segment offers clinical instruments, reagents, consumables, software, and services used to diagnose disease and make treatment decisions. The company was founded by Steven M. Rales and Mitchell P. Rales in 1984 and is headquartered in Washington, DC.
Attention! Trading on the stock market involves financial risks and is not suitable for everyone. The www.stocks-expert.com does not provide financial market trading services; it is for informational purposes only and is not responsible for the consequences of your trading decisions or the operation of the software. Before starting to trade in any markets, make sure you understand the risks associated with trading and that you have a sufficient level of training.